Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyOhio Medicaid Beyfortus Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentOhio Department of MedicaidPolicy N/A

    Coverage and Payment of Beyfortus® (nirsevimab)

    Customize your policy alerts

    Sign up for all Ohio Department of Medicaid policy alerts

    Know when Ohio Department of Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This directive governs Medicaid managed care plan coverage, prior authorization, and payment treatment for Beyfortus used to prevent RSV in infants. Plans may remove coverage for the drug product because it can be obtained through the Vaccines for Children Program, but must continue covering its administration component.

    Policy Summary
    PayerOhio Department of Medicaid
    PolicyCoverage and Payment of Beyfortus® (nirsevimab)
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateMarch 19, 2025
    Next Review DateN/A
    Key ActionContinue covering the administration component for Beyfortus even if coverage for the drug product is removed.
    SourceLink
    POLICY UPDATE CHANGES

    Plans may remove coverage for Beyfortus because the product can be sourced through the Vaccines for Children Program.

    Plans remain required to cover the administration component for Beyfortus.

    The prior direction to align MCO coverage with Fee-for-Service coverage without prior authorization for medical claims using CPT 90380 and 90381 is superseded by updated product-coverage direction.

    2CPT codes identified for medical-claim billing
    No prior authorizationPrior authorization for medical-claim billing
    May be removed
    Policy Summary
    PayerOhio Department of Medicaid
    PolicyCoverage and Payment of Beyfortus® (nirsevimab)
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateMarch 19, 2025
    Next Review DateN/A
    Key ActionContinue covering the administration component for Beyfortus even if coverage for the drug product is removed.
    SourceLink
    On This Page
    Beyfortus Product and Administration CoverageMedical-Claim Billing and ImplementationRequired Plan and Billing ActionsKey Coverage Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Beyfortus drug product coverage
    RequiredVaccine administration coverage

    Beyfortus Product and Administration Coverage

    Beyfortus Product and Administration Coverage

    Coverage and payment requirements for Beyfortus® (nirsevimab) are as follows; product coverage and administration payment are addressed separately.

    ALL of the following apply

    • Beyfortus® (nirsevimab) is used for prevention of respiratory syncytial virus (RSV) in infants.
    • When Beyfortus® is covered and billed on a medical claim using CPT 90380 or 90381, prior authorization is not required.

      ODM requested that Managed Care Organization coverage align with Medicaid Fee-for-Service by not requiring prior authorization for these medical-claim submissions.

    • Plans may remove coverage for the Beyfortus® product because it can be sourced through the Vaccines For Children (VFC) Program.No earlier than April 1, 2025

      Plans were asked to finish the 2024–2025 RSV season before implementing product-coverage changes and to submit updated clinical coverage policies to ODM for review, as applicable.

    • The administration component must remain covered and payable even if the plan removes coverage for the Beyfortus® product.

      Product coverage changes do not eliminate the requirement to cover administration.

    Medical-Claim Billing and Implementation

    Covered CPT CodesCPTCovered
    90380CPT code for Beyfortus medical-claim billing
    90381CPT code for Beyfortus medical-claim billing
    Product Coverage Removal
    Earliest implementation dateApril 1, 2025

    Required Plan and Billing Actions

    Prior Authorization

    No prior authorization for medical-claim billing

    Do not require prior authorization when Beyfortus is billed on a medical claim using CPT 90380 or 90381, consistent with Medicaid Fee-for-Service treatment.

    • CPT 90380
    • CPT 90381
    Documentation Required

    Implement product coverage changes on schedule

    Plans may remove coverage for Beyfortus because the product can be sourced through the Vaccines for Children (VFC) Program. Do not implement the coverage change before April 1, 2025, and revise and submit updated clinical coverage policies to ODM for review as applicable.

    • Earliest implementation date: April 1, 2025
    • Submit updated clinical coverage policies to ODM for review as applicable

    Key Coverage Terms

    Vaccines for Children (VFC) Program
    Program nameVaccines for Children (VFC) Program
    PurposeFederal program through which the Beyfortus product can be sourced
    Coverage implicationPlans may remove separate coverage for Beyfortus because the product can be sourced through the VFC Program
    Administration Component
    DefinitionThe administration component is the vaccine service component separate from the Beyfortus drug product
    Coverage requirementPlans are still required to cover the administration component for the vaccine product
    Effect of product coverage removal
    Billing Rule

    Continue paying for vaccine administration

    Continue covering the administration component for the vaccine product even if coverage for the Beyfortus drug product is removed.

    Administration coverage must continue even if coverage for the Beyfortus drug product is removed